Celltrion (068270.KS) is accelerating commercialization procedures to secure U.S. Food and Drug Administration (FDA) Fast Track designation for its next-generation novel drug candidates. The company aims to sequentially place follow-on projects onto the Fast Track pathway, building on proven results from its lead pipeline. With four novel drug candidates — including antibody-drug conjugates (ADCs) and multi-specific antibodies — currently progressing through global Phase 1 clinical trials, expectations are growing for shortened approval timelines and earlier commercialization.
According to pharmaceutical and biotech industry sources on Wednesday, Celltrion is concentrating its efforts on securing mid-to-long-term growth drivers centered on novel drugs, starting with the Fast Track designation of its anticancer candidate CT-P70. The company is reinforcing a virtuous cycle in which stable revenue generated from its core biosimilar business is reinvested into novel drug research and development. With CT-P70 leading the way after its early data demonstrated recognized potential, Celltrion's push into high-value innovative drug development is becoming increasingly tangible, strengthening its position as a comprehensive pharmaceutical company in the global market.
The FDA's Fast Track program was introduced to help accelerate the commercialization of treatments for serious conditions. Once designated, developers can maintain close and ongoing communication channels with the FDA throughout the entire clinical process, enabling rapid consultation on clinical design and development strategy. Designated drugs can also become eligible for Priority Review and Accelerated Approval, which shorten review timelines. Building on CT-P70's achievement, Celltrion is pursuing Fast Track approval within this year for three additional candidates currently in Phase 1 trials: ADC candidates CT-P71 and CT-P73, and multi-specific antibody candidate CT-P72.
The diversification of Celltrion's novel drug portfolio is being advanced not only through proprietary technology but also via open innovation through external partnerships. The company is currently conducting joint research with promising domestic and international biotechs to discover anticancer and autoimmune disease drug candidates. Notably, in the obesity treatment space — an area of growing attention — Celltrion has begun developing oral and long-acting formulations that offer greater convenience compared to existing injectable treatments, moving to secure a position in next-generation modalities. This all-encompassing investment strategy is interpreted as a plan to maximize synergies with the global direct-sales network built through its biosimilar business, rapidly capturing market share from the initial launch of novel drugs.
This aggressive pipeline expansion aligns with the future growth vision laid out by Celltrion Group Chairman Seo Jung-jin. At the annual general meeting in March, Chairman Seo detailed a blueprint to raise the revenue share of novel drugs to more than half relative to biosimilars. Accordingly, Celltrion is broadening its scope well beyond antibody-centric modalities such as ADCs and multi-specific antibodies into areas including next-generation obesity treatments, deepening the portfolio's reach. The overarching plan is to become a bona fide global big pharma through a dual-track strategy that advances both proprietary platform technology and wide-ranging external collaborations.
In the securities sector, analysts are moving to reassess Celltrion's corporate value by adding the growth potential of its novel drug pipeline to its existing valuation. Jeong Jae-won, a researcher at iM Securities, noted in a recent report, "Because CT-P70 has received FDA Fast Track designation, there is momentum for rapid entry into late-stage clinical trials based on data readout results," adding, "Stable biosimilar performance combined with clinical achievements in new modalities is expected." Kim Jun-young, a researcher at Meritz Securities, also assessed that "Celltrion is transforming into a comprehensive pharmaceutical company that includes novel drug development through proprietary R&D and open innovation," adding, "Sustained growth deserves close attention."
IV Research, an independent research firm, analyzed that Celltrion's novel drug pipeline will gradually serve as a valuation premium factor on top of the company's corporate value, which had been suppressed by its classification as a pure biosimilar company. The firm assessed that Celltrion has entered a phase where its past valuation framework is being redefined. In particular, it projected that this year will mark the inaugural year in which clinical trials gain full momentum and novel drug value begins to be added to the company's core biosimilar earnings.
A Celltrion official said, "The Fast Track designation is the result of the FDA recognizing the company's commitment to delivering innovative drugs more quickly in the serious disease space," adding, "This will serve as an opportunity to maximize efficiency in the development and review process." The official further emphasized, "We will do our utmost to become a bona fide global big pharma through the rapid development of follow-on drug candidates and the strengthening of our portfolio."